Table 3.
Ongoing clinical trials in BTC.
| Type of Trial | Treatments | ClinicalTrials.gov Identifier |
|---|---|---|
| Phase 0 | HAI of FURD + dexamethasone vs. HAI of FURD + dexamethasone + gem vs. HAI of FURD + dexamethasone + gem + oxaliplatin | |
| Phase I | Acelarin + Cisplatin | |
| Phase I | DKN-01 + gem + cisplatin | |
| Phase I | HAI of FURD + dexamethasone + gem | |
| Phase I | Pazopanib + GSK1120212 | |
| Phase I/II | Amphinex + gem vs. gem + cisplatin | |
| Phase I/II | ARQ 087 | |
| Phase I/II | CX-4945 + gem + cisplatin | |
| Phase I/II | Cytokine induced killer cells | |
| Phase I/II | Gem + cisplatin + MEK162 | |
| Phase II | Abraxane + gem + cisplatin | |
| Phase II | ASLAN001 | |
| Phase II | BGJ398 (pan FGFR kinase inhibitor) | |
| Phase II | Cabozantinib | |
| Phase II | Ceritinib (LDK378) | |
| Phase II | FOLFIRINOX | |
| Phase II | Gem + cisplatin + selumetinib | |
| Phase II | Gem + oxaliplatin + capecitabine vs. gem + oxaliplatin + capecitabine + panitumumab | |
| Phase II | Gem + oxaliplatin + capecitabine + panitumumab vs. gem + oxaliplatin + catecitabine + bevacizumab | |
| Phase II | HAI of FURD + dexamethasone + gem + oxaliplatin | |
| Phase II | Low-dose radiation + gem + cisplatin | |
| Phase II | Nab-paclitaxel + gem | |
| Phase II | Pembrolizumab | |
| Phase II | Ramucirumab | |
| Phase II | Refametinib | |
| Phase II | Regorafenib | |
| Phase II | RRx-001 + gem + cisplatin | |
| Phase II | Sunitinib | |
| Phase Ha | Trametinib | |
| Phase II/III | Radiofrequency ablation + cytokine-induced killer cells (CIK) transfusion | |
| Phase III | Gem + cisplatin | |
| Phase III | Gem + oxaliplatin vs. capecitabine | |
| Phase III | Oxaliplatin |
5-FU - fluorouracil, FOLFIRI - irinotecan with fluorouracil (5FU) and folinic acid, FOLFIRINOX - FOLFIRI plus oxaliplatin, FURD - floxuridine, Gem - gemcitabine, HAI - hepatic arterial infusion.